Home › Gender Dysphoria › NCT07624747
Brain Health in Transgender Adults
Cerebral Blood Flow and Neurocognitive Performance in Adults Undergoing Gender-affirming Hormone Therapy
Who can join
Ages 18 to 45 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * intention to undergo GAHT Exclusion Criteria: * BMI greater than 40 kg/m2 * Age greater than 45 yrs * Blood pressure greater than 140/90 (stage II hypertension) * A current diagnosis of type II diabetes * History of traumatic brain injury/concussion, stroke, or seizures * Are post-menopausal * Previously taken hormone therapy medications * Self-reported pregnancy (no pregnancy test)
About the study
The purpose of this study is to test whether and how a person's brain changes in the first few months after starting gender affirming hormone therapy (GAHT). The investigators want to know if GAHT changes: 1) cerebral blood flow (CBF), 2) brain structure, connectivity, and cognitive task performance, and 3) neurocognitive function (memory, attention, executive function, processing speed). 36 male at birth and 36 female at birth participants will conduct baseline studies prior to GAHT, with a second identical set of study visits 4-6 months after GAHT begins.
What is being tested
- Magnetic Resonance Imaging (device)
- Cognition and Health Tests (other)
- Optional Exercise Test (other)
Sponsor: University of Wisconsin, Madison · Participants: 72 · Started: Oct 14, 2025
Contact the study team
- Shawn Bolin, MS · Phone: 608-263-6308
Official record on ClinicalTrials.gov — NCT07624747
Locations in the U.S.
| Wisconsin | UW School of Medicine and Public Health, Madison |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.